Avalo Therapeutics Net Income Over Time
| AVTX Stock | USD 14.61 0.60 4.28% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Avalo Therapeutics Performance and Avalo Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avalo Therapeutics. If investors know Avalo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Avalo Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (13.42) | Revenue Per Share | Quarterly Revenue Growth (0.66) | Return On Assets | Return On Equity |
The market value of Avalo Therapeutics is measured differently than its book value, which is the value of Avalo that is recorded on the company's balance sheet. Investors also form their own opinion of Avalo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avalo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avalo Therapeutics' market value can be influenced by many factors that don't directly affect Avalo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Avalo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Avalo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Avalo Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Avalo Therapeutics and related stocks such as Prelude Therapeutics, Inventiva Sa, and Eupraxia Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRLD | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (27.6 M) | (56.9 M) | (110.8 M) | (107.3 M) | (121.8 M) | (127.2 M) | (114.5 M) | (120.2 M) |
| IVA | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.5 M) | (8.8 M) | (7 M) | (17.2 M) | (33.6 M) | (30.2 M) | (31.6 M) | (49.6 M) | (54.3 M) | (110.4 M) | (184.2 M) | (165.8 M) | (157.5 M) |
| EPRX | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (13.2 M) | (7.4 M) | (4 M) | (18 M) | (18.5 M) | (28.2 M) | (36.7 M) | (33 M) | (31.4 M) |
| CRBU | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (34.3 M) | (66.9 M) | (99.4 M) | (102.1 M) | (149.1 M) | (134.2 M) | (127.5 M) |
| CHRS | (33 M) | (33 M) | (33 M) | (53.6 M) | (87.1 M) | (223.3 M) | (127.3 M) | (238.2 M) | (209.3 M) | 89.8 M | 132.2 M | (287.1 M) | (291.8 M) | (237.9 M) | 28.5 M | 25.7 M | 26.9 M |
| OBIO | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (23 M) | (33.6 M) | (49.1 M) | (61 M) | (54.9 M) | (57.7 M) |
| AARD | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (7.2 M) | (20.6 M) | (18.5 M) | (19.5 M) |
| TNYA | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (38.4 M) | (69.7 M) | (123.7 M) | (124.1 M) | (111.1 M) | (100 M) | (105 M) |
| ENTA | 7.9 M | 21.4 M | 9.6 M | 34.4 M | 79 M | 21.7 M | 17.7 M | 72 M | 46.4 M | (36.2 M) | (79 M) | (121.8 M) | (133.8 M) | (116 M) | (81.9 M) | (73.7 M) | (70 M) |
| BDTX | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (8.9 M) | (35.3 M) | (67.3 M) | (125.6 M) | (91.2 M) | (82.4 M) | (69.7 M) | (62.7 M) | (65.8 M) |
Avalo Therapeutics and related stocks such as Prelude Therapeutics, Inventiva Sa, and Eupraxia Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Avalo Therapeutics financial statement analysis. It represents the amount of money remaining after all of Avalo Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Avalo Therapeutics | AVTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 540 Gaither Road, |
| Exchange | NASDAQ Exchange |
USD 14.61
Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.